TY - JOUR
T1 - OARSI Clinical Trials Recommendations
T2 - Design, conduct, and reporting of clinical trials for knee osteoarthritis
AU - McAlindon, T. E.
AU - Driban, J. B.
AU - Henrotin, Y.
AU - Hunter, D. J.
AU - Jiang, G. L.
AU - Skou, S. T.
AU - Wang, S.
AU - Schnitzer, T.
N1 - Funding Information:
Yves Henrotin – YH received honoraria from Artialis, Bioiberica, Danone, Expanscience, Ibsa, Merck, Pierre Fabre, Synolyne Pharma, Tilman. YH is the founder and owner of Artialis SA a biomarker manufacturer and Synolyne Pharma, two spin-off companies of the University of Liège. YH also received unrestricted educational grant from Bioiberica, Expanscience, Royal Canin, Artialis, and Nestle.
Publisher Copyright:
© 2015 Osteoarthritis Research Society International.
PY - 2015
Y1 - 2015
N2 - The goal of this document is to update the original OARSI recommendations specifically for the design, conduct, and reporting of clinical trials that target symptom or structure modification among individuals with knee osteoarthritis (OA).To develop recommendations for the design, conduct, and reporting of clinical trials for knee OA we initially drafted recommendations through an iterative process. Members of the working group included representatives from industry and academia. After the working group members reviewed a final draft, they scored the appropriateness for recommendations. After the members voted we calculated the median score among the nine members of the working group who completed the score.The document includes 25 recommendations regarding randomization, blocking and stratification, blinding, enhancing accuracy of patient-reported outcomes (PRO), selecting a study population and index knee, describing interventions, patient-reported and physical performance measures, structural outcome measures, biochemical biomarkers, and reporting recommendations.In summary, the working group identified 25 recommendations that represent the current best practices regarding clinical trials that target symptom or structure modification among individuals with knee OA. These updated recommendations incorporate novel technologies (e.g., magnetic resonance imaging (MRI)) and strategies to address the heterogeneity of knee OA.
AB - The goal of this document is to update the original OARSI recommendations specifically for the design, conduct, and reporting of clinical trials that target symptom or structure modification among individuals with knee osteoarthritis (OA).To develop recommendations for the design, conduct, and reporting of clinical trials for knee OA we initially drafted recommendations through an iterative process. Members of the working group included representatives from industry and academia. After the working group members reviewed a final draft, they scored the appropriateness for recommendations. After the members voted we calculated the median score among the nine members of the working group who completed the score.The document includes 25 recommendations regarding randomization, blocking and stratification, blinding, enhancing accuracy of patient-reported outcomes (PRO), selecting a study population and index knee, describing interventions, patient-reported and physical performance measures, structural outcome measures, biochemical biomarkers, and reporting recommendations.In summary, the working group identified 25 recommendations that represent the current best practices regarding clinical trials that target symptom or structure modification among individuals with knee OA. These updated recommendations incorporate novel technologies (e.g., magnetic resonance imaging (MRI)) and strategies to address the heterogeneity of knee OA.
KW - Clinical trial
KW - Consensus statement
KW - Knee
KW - Osteoarthritis
UR - http://www.scopus.com/inward/record.url?scp=84933519200&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84933519200&partnerID=8YFLogxK
U2 - 10.1016/j.joca.2015.03.005
DO - 10.1016/j.joca.2015.03.005
M3 - Review article
C2 - 25952346
AN - SCOPUS:84933519200
SN - 1063-4584
VL - 23
SP - 747
EP - 760
JO - Osteoarthritis and Cartilage
JF - Osteoarthritis and Cartilage
IS - 5
ER -